Michael Peel / Financial Times:
AstraZeneca signs a deal worth up to $247M with US-based Absci to harness its AI tech for large-scale protein analysis and design an antibody to fight cancer — Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Lees verder op Tech Meme